BioCentury | Oct 2, 2020
Finance

Next stop IPO? Olema adds to momentum with $85M series C

...an oral complete estrogen receptor antagonist (CERAN) in a Phase I/II trial for advanced and/or metastatic estrogen receptor-positive...
BioCentury | Sep 18, 2020
Management Tracks

Former AZ CMO Bohen brings his cancer chops to Olema

...is an oral complete estrogen receptor antagonist (CERAN) in a Phase I/II trial for advanced and/or metastatic estrogen receptor-positive...
BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...that activates the unfolded protein response in estrogen receptor-positive...
BioCentury | Aug 22, 2020
Finance

Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

...of another PROTAC therapy, ARV-471, to treat estrogen receptor-positive...
BioCentury | Aug 8, 2020
Translation in Brief

Cocrystal’s COVID-19 antivirals; plus a portable breast cancer diagnostic, Tarveda mini-drug conjugate for solid tumors, and more

...and reversed the altered social novelty responses. Targets 3CLpro - 3C-like protease ER (ESR) - Estrogen receptor...
...subunit alpha polypeptide (PIK3CA) (p110alpha) Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Estrogen receptor 1 (ER) (ESR1) Estrogen receptor...
BioCentury | Jul 24, 2020
Finance

Olema aims to deploy $54M round to carve its niche in breast cancer

...Olema’s plans for its oral selective estrogen receptor degrader attracted a crossover-laden syndicate to the San Francisco...
...kinase 4 CDK6 - Cyclin dependent kinase 6 ER (ESR1) - Estrogen receptor 1 ESR2 - Estrogen receptor...
...Capital Janus Henderson Investors Cormorant Asset Management RA Capital Management Wellington Management Surveyor Capital Venrock Associates Foresite Capital Management AstraZeneca plc Estrogen receptor 1 (ER) (ESR1) Estrogen receptor...
BioCentury | Jun 2, 2020
Product Development

Sanofi makes case for why its first cancer drug in a decade can take on Darzalex

...that of other genetically defined NSCLC subsets. The last pillar is an orally delivered selective estrogen receptor...
...REGN2810, SAR439684) Sanofi Carcinoembryonic antigen (CEA)-related cell adhesion molecule 5 (CEACAM5) (CD66e) CD38 Programmed cell death 1 (PD-1) (PDCD1) (CD279) Estrogen receptor...
BioCentury | May 13, 2020
Product Development

Arvinas unveils first efficacy signal for targeted protein degradation, points to opportunity in resistant cancers

...its two lead PROTACs (proteolysis targeting chimeras). ARV-110 and ARV-471 tag the androgen receptor and estrogen receptor...
BioCentury | Mar 12, 2020
Product Development

Targeted degradation gets another bump with Kymera’s $102M raise

...expected to read out this half. The company also has ARV-471, a PROTAC targeting the estrogen receptor...
BioCentury | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

...Sanofi to direct more money and resources to cancer. In oncology, Sanofi has earmarked an estrogen receptor...
Items per page:
1 - 10 of 959